A comprehensive view of Biomedical Advanced Research and Development Authority (BARDA). This page highlights a small sample of our full coverage.
For real-time access, please log in to your R&D/Patents Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Moderna may halt midstage Zika vaccine development without additional external funding despite US financial support; decision draws into question the future of the most advanced vaccine in the company's public health pipeline
Published: March 15, 2024 by FierceBiotech
BARDA selects Thermo Fisher Scientific's PPD clinical research business to conduct Phase 2 trial investigating treatments for acute respiratory distress syndrome; study to evaluate three host-directed therapeutics at multiple sites in the US
Published: January 11, 2024 by Wireless News
CastleVax receives BARDA Project NextGen award valued at up to US$338M to advance intranasal NDV-based COVID-19 booster vaccine into Phase 2b clinical efficacy testing
Published: October 19, 2023 by Targeted News Service (Press Releases)
Regeneron receives funding from US Government’s Project NextGen to support clinical development of new COVID-19 monoclonal antibody therapy for the prevention of SARS-CoV-2 infection; funding could total $326.0M
Published: August 22, 2023 by Regeneron Pharmaceuticals Inc.

Ask us about our R&D/Patents market view

Trending Chart

Interactive chart with headline count